Neuropathic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2018

• Publication date: September 2011

Neuropathic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Summary GlobalData, the industry analysis specialist, has released its new report, “Neuropathic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Neuropathic Pain Therapeutics market. The report identifies the key trends shaping and driving the g...

Neuropathic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Neuropathic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Neuropathic Pain Therapeutics market. The report identifies the key trends shaping and driving the global Neuropathic Pain Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Neuropathic Pain Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Neuropathic Pain Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Neuropathic Pain Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Neuropathic Pain Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Neuropathic Pain Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Neuropathic Pain Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Neuropathic Pain Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Neuropathic Pain Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Neuropathic Pain Therapeutics market landscape? – Identify, understand and capitalize.

Therapy Industry in the United Kingdom

1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Neuropathic Pain Therapeutics - Introduction 7
2.1 Disease Overview 7
2.1.1 Chronic Pain is Further Divided Into 8
2.2 Etiology and Pathophysiology 9
2.3 Signs and Symptoms 12
2.4 Epidemiology 13
2.5 Diagnosis 14
2.5.1 McGill Pain Questionnaire (MPQ) 15
2.5.2 Neuropathic Pain Scale (NPS) 15
2.5.3 Quantitative Sensory Testing (QST) 15
2.6 Treatment and Management Pattern 15
2.7 Referral Pathway 17
2.8 GlobalData Pipeline Report Guidance 18
3 Neuropathic Pain Therapeutics - Market Characterization 19
3.1 Neuropathic Pain Therapeutics Market Size (2005–2010) – Global 19
3.2 Neuropathic Pain Therapeutics Market Forecast (2010–2018) – Global 20
3.3 Neuropathic Pain Therapeutics Market Size (2005–2010) – The US 21
3.4 Neuropathic Pain Therapeutics Market Forecast (2010–2018) – The US 22
3.5 Neuropathic Pain Therapeutics Market Size (2005–2010) – The UK 23
3.6 Neuropathic Pain Therapeutics Market Forecast (2010–2018) – The UK 24
3.7 Neuropathic Pain Therapeutics Market Size (2005–2010) – France 25
3.8 Neuropathic Pain Therapeutics Market Forecast (2010–2018) – France 26
3.9 Neuropathic Pain Therapeutics Market Size (2005–2010) – Germany 27
3.10 Neuropathic Pain Therapeutics Market Forecast (2010–2018) – Germany 28
3.11 Neuropathic Pain Therapeutics Market Size (2005–2010) – Italy 29
3.12 Neuropathic Pain Therapeutics Market Forecast (2010–2018) – Italy 30
3.13 Neuropathic Pain Therapeutics Market Size (2005–2010) – Spain 31
3.14 Neuropathic Pain Therapeutics Market Forecast (2010–2018) – Spain 32
3.15 Neuropathic Pain Therapeutics Market Size (2005–2010) – Japan 33
3.16 Neuropathic Pain Therapeutics Market Size (2010–2018) – Japan 34
3.17 Drivers and Barriers for the Neuropathic Pain Therapeutics Market 35
3.17.1 Drivers for Neuropathic Pain Market 35
3.17.2 Barriers for Neuropathic Pain Market 35
3.18 Opportunity and Unmet Need Analysis 35
3.19 Key Takeaway 37
4 Neuropathic Pain Therapeutics - Competitive Assessment 38
4.1 Overview 38
4.2 Strategic Competitor Assessment 38
4.3 Product Profiles for the Major Marketed Products in the Neuropathic Pain Therapeutics Market 39
4.3.1 Lyrica (pregabalin) 39
4.3.2 Cymbalta (duloxetine) 40
4.3.3 Lidoderm (lidocaine patch 5%) 42
4.3.4 Neurontin (gabapentin) 43
4.3.5 Qutenza (capsaicin) 8% Patch 44
4.4 Key Takeaway 46
5 Global Neuropathic Pain Market - Pipeline Assessment 47
5.1 Overview 47
5.2 Strategic Pipeline Assessment 47
5.3 Neuropathic Pain Therapeutics Pipeline – Pipeline by Phases of Development 47
5.3.1 Neuropathic Pain Therapeutics – Regulatory Filed Products 48
5.3.2 Neuropathic Pain Therapeutics – Phase III Pipeline 48
5.3.3 Neuropathic Pain Therapeutics – Phase II Pipeline 49
5.3.4 Neuropathic Pain Therapeutics – Phase I Pipeline 50
5.3.5 Neuropathic Pain Market – Discovery and Pre-Clinical Pipeline 51
5.3.6 Technology Trends Analytic Framework 53
5.4 Neuropathic Pain Therapeutics Market – Pipeline by Mechanism of Action 55
5.5 Neuropathic Pain Therapeutics – Promising Drugs Under Clinical Development 56
5.6 Molecule Profile for Promising Drugs under Clinical Development 57
5.6.1 AVP-923 (Zenvia) 57
5.6.2 Fentora (fentanyl buccal tablet) 58
5.6.3 Nucynta ER (tapentadol) 59
5.6.4 AS-3201 (ranirestat) 60
5.7 Key Takeaway 61
6 Neuropathic Pain Therapeutics: Clinical Trials Mapping 62
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 62
6.2 Clinical Trials by Phase 63
6.3 Clinical Trials by Trial Status 64
6.4 Clinical Trials by Sponsors 65
6.5 Top Companies Participating in Neuropathic Pain Therapeutics Clinical Trials 67
7 Neuropathic Pain Therapeutics - Strategic Assessment 68
7.1 Key Events Impacting the Future Market 68
7.2 Neuropathic Pain Therapeutics: Implications for Future Market Competition 69
8 Neuropathic Pain Therapeutics - Future Players 71
8.1 Introduction 71
8.2 Company Profiles 72
8.2.1 Pfizer Inc. 72
8.2.2 Grunenthal GmbH 76
8.2.3 Avanir Pharmaceuticals 78
8.2.4 Cephalon Inc. 79
8.2.5 Endo Pharmaceuticals 82
8.2.6 Dainippon Sumitomo Pharma Co., Ltd. 84
8.2.7 NeurogesX Inc. 88
8.2.8 Other Companies in the Neuropathic Pain Therapeutics Market 91
9 Neuropathic Pain Therapeutics - Licensing and Partnership Deals 99
10 Neuropathic Pain Therapeutics - Appendix 106
10.1 Market Definitions 106
10.2 Abbreviations 106
10.3 Research Methodology 107
10.3.1 Coverage 108
10.3.2 Secondary Research 108
10.3.3 Forecasting 108
10.3.4 Primary Research 111
10.3.5 Expert Panel Validation 111
10.4 Contact Us 111
10.5 Disclaimer 111
10.6 Bibliography 112

List of Tables

Table 1: Differentiation of Chronic Pain from Acute Pain 7
Table 2: Neuropathic Pain Therapeutics Market, Global, Revenue ($bn), 2005–2010 19
Table 3: Neuropathic Pain Therapeutics Market, Global, Forecast ($bn), 2010–2018 20
Table 4: Neuropathic Pain Therapeutics Market, The US, Revenue ($bn), 2005–2010 21
Table 5: Neuropathic Pain Therapeutics Market, The US, Forecast ($bn), 2010–2018 22
Table 6: Neuropathic Pain Therapeutics Market, The UK, Revenue ($m), 2005–2010 23
Table 7: Neuropathic Pain Therapeutics Market, The UK, Forecast ($m), 2010–2018 24
Table 8: Neuropathic Pain Therapeutics Market, France, Revenue ($m), 2005–2010 25
Table 9: Neuropathic Pain Therapeutics Market, France, Forecast ($m), 2010–2018 26
Table 10: Neuropathic Pain Therapeutics Market, Germany, Revenue ($m), 2005–2010 27
Table 11: Neuropathic Pain Therapeutics Market, Germany, Forecast ($m), 2010–2018 28
Table 12: Neuropathic Pain Therapeutics Market, Italy, Revenue ($m), 2005–2010 29
Table 13: Neuropathic Pain Therapeutics Market, Italy, Forecast ($m), 2010–2018 30
Table 14: Neuropathic Pain Therapeutics Market, Spain, Revenue ($m), 2005–2010 31
Table 15: Neuropathic Pain Therapeutics Market, Spain, Forecast ($m), 2010–2018 32
Table 16: Neuropathic Pain Therapeutics Market, Japan, Revenue ($m), 2005–2010 33
Table 17: Neuropathic Pain Therapeutics Market, Japan, Forecast ($bn), 2010–2018 34
Table 18: Neuropathic Pain Therapeutics, Regulatory Filed Products, 2011 48
Table 19: Neuropathic Pain Therapeutics, Phase III Pipeline, 2011 48
Table 20: Neuropathic Pain Therapeutics, Phase II Pipeline, 2011 49
Table 21: Neuropathic Pain Therapeutics, Phase I Pipeline, 2011 50
Table 22: Neuropathic Pain Therapeutics, Discovery and Pre-Clinical Pipeline, 2011 51
Table 23: Neuropathic Pain Therapeutics – Most Promising Drugs Under Clinical Development, 2011 56
Table 24: Neuropathic Pain Therapeutics, Clinical Trials by Country, 2011 62
Table 25: Neuropathic Pain Therapeutics - Clinical Trials by Phase, 2011 63
Table 26: Neuropathic Pain Therapeutics, Clinical Trials by Status, 2011 64
Table 27: Neuropathic Pain Therapeutics, Prominent Sponsors, 2011 66
Table 28: Neuropathic Pain Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 67
Table 29: Pfizer Inc., Pain Management, Pipeline, 2011 74
Table 30: Pfizer, Inc., Deals, 2010–2011 74
Table 31: Grunenthal GmbH, Pain Management, Pipeline, 2011 76
Table 32: Grunenthal GmbH, Deals, 2010-2011 77
Table 33: Avanir Pharmaceuticals – Pain Management, Pipeline, 2011 78
Table 34: Avanir Pharmaceuticals – Deals, 2009-2011 79
Table 35: Cephalon, Inc., Pain Management Pipeline, 2011 80
Table 36: Cephalon Inc., Deals, 2010–2011 81
Table 37: Endo Pharmaceuticals, Pain Management, Pipeline, 2011 84
Table 38: Endo Pharmaceuticals, Deals, 2011 84
Table 39: Dainippon Sumitomo Pharma Co., Ltd, Pain Management, Pipeline, 2011 85
Table 40: Dainippon Sumitomo Pharma Co., Ltd., Deals, 2011 86
Table 41: NeurogesX, Inc., Pain Management, Pipeline, 2011 89
Table 42: NeurogesX Inc., Deals, 2011 90
Table 43: Neuropathic Pain Therapeutics Market, Future Players 91
Table 44: Neuropathic Pain Therapeutics, Global, Deals, 2009-2011 99

List of Figures

Figure 1: Classification of Chronic Pain and Representative Indications 8
Figure 2: Development of Neuropathic Pain 9
Figure 3: Etiology of Neuropathic Pain 10
Figure 4: Pathophysiological Mechanisms of Neuropathic Pain 10
Figure 5: Pathophysiology of Neuropathic Pain 11
Figure 6: Sign s and Symptoms of Neuropathic Pain 12
Figure 7: Signs and Symptoms of Neuropathic Pain 13
Figure 8: Pain Measurement Scale – Faces Rating Scale 14
Figure 9: Treatment Approach in Neuropathic Pain 16
Figure 10: Neuropathic Pain Treatment Pathway 16
Figure 11: Referral Pathway for Neuropathic Pain 17
Figure 12: Neuropathic Pain Therapeutics Market, Global, Revenue ($bn), 2005–2010 19
Figure 13: Neuropathic Pain Therapeutics Market, Global, Forecast ($bn), 2010–2018 20
Figure 14: Neuropathic Pain Therapeutics Market, The US, Revenue ($bn), 2005–2010 21
Figure 15: Neuropathic Pain Therapeutics Market, The US, Forecast ($bn), 2010–2018 22
Figure 16: Neuropathic Pain Therapeutics Market, The UK, Revenue ($m), 2005–2010 23
Figure 17: Neuropathic Pain Therapeutics Market, The UK, Forecast ($m), 2010–2018 24
Figure 18: Neuropathic Pain Therapeutics Market, France, Revenue ($m), 2005–2010 25
Figure 19: Neuropathic Pain Therapeutics Market, France, Forecast ($m), 2010–2018 26
Figure 20: Neuropathic Pain Therapeutics Market, Germany, Revenue ($m), 2005–2010 27
Figure 21: Neuropathic Pain Therapeutics Market, Germany, Forecast ($m), 2010–2018 28
Figure 22: Neuropathic Pain Therapeutics Market, Italy, Revenue ($m), 2005–2010 29
Figure 23: Neuropathic Pain Therapeutics Market, Italy, Forecast ($m), 2010–2018 30
Figure 24: Neuropathic Pain Therapeutics Market, Spain, Revenue ($m), 2005–2010 31
Figure 25: Neuropathic Pain Therapeutics Market, Spain, Forecast ($m), 2010–2018 32
Figure 26: Neuropathic Pain Therapeutics Market, Japan, Revenue ($m), 2005–2010 33
Figure 27: Neuropathic Pain Therapeutics Market, Japan, Revenue ($bn), 2010–2018 34
Figure 28: Opportunity and Unmet Need (Oral Drugs) in the Neuropathic Pain Therapeutics Market, 2010 36
Figure 29: Opportunity and Unmet Need (Topical Patches) in the Neuropathic Pain Therapeutics Market, 2010 37
Figure 30: Strategic Competitor Assessment of the Major Marketed Products in Neuropathic Pain, 2010 38
Figure 31: Neuropathic Pain Therapeutics – Pipeline by Phase of Development, 2011 47
Figure 32: Neuropathic Pain Therapeutics, Technology Trends Analytics Framework, 2011 53
Figure 33: Neuropathic Pain Therapeutics, Technology Trends Analytics Framework, Description, 2011 54
Figure 34: Neuropathic Pain Therapeutics, Pipeline by Mechanism of Action (%), 2011 55
Figure 35: Fentora (fentanyl buccal tablet): Chemical Structure 58
Figure 36: Nucynta ER (tapentadol): Chemical Structure 59
Figure 37: AS-3201 (ranirestat): Chemical Structure 60
Figure 38: Neuropathic Pain Therapeutics, Clinical Trials by Country, 2011 62
Figure 39: Neuropathic Pain Therapeutics, Clinical Trials by Phase (%), 2011 63
Figure 40: Neuropathic Pain Therapeutics, Clinical Trials by Status, 2011 64
Figure 41: Neuropathic Pain Therapeutics, Overall Sponsors (%), 2011 65
Figure 42: Neuropathic Pain Therapeutics, Prominent Sponsors (%), 2011 66
Figure 43: Neuropathic Pain Therapeutics, Top Companies Participating in Clinical Trials, 2011 67
Figure 44: Neuropathic Pain Therapeutics Market, Drivers and Barriers, 2011 68
Figure 45: Implications for Future Market Competition in the Neuropathic Pain Market, 2011 69
Figure 46: Neuropathic Pain Therapeutics Market, Pipeline by Company, 2011 71
Figure 47: GlobalData Market Forecasting Model 110

Companies Mentioned
Pfizer Inc.
Grunenthal GmbH
Avanir Pharmaceuticals
Cephalon Inc.
Endo Pharmaceuticals
Dainippon Sumitomo Pharma Co., Ltd.
NeurogesX Inc.